Ernexa Therapeutics CEO Sanjeev Luther to Join Virtual Investor Closing Bell Series Webcast

Reuters

Feb 20

Ernexa <a href="https://laohu8.com/S/LENZ">Therapeutics</a> CEO Sanjeev Luther to Join Virtual Investor Closing Bell Series Webcast

Ernexa Therapeutics (Nasdaq: ERNA) said its President and CEO, Sanjeev Luther, will participate in the Virtual Investor Closing Bell Series on Wednesday, February 25, 2026 at 4:00 PM ET, providing a corporate overview and business outlook with a live Q&A. Registration is available here: https://www.globenewswire.com/Tracker?data=RLDub8FFW7byVYLqZpCIzF9-aHU5aLAr8cfx7zgP335FFgqUD_hGfE9JePoYboIN-ts5V3N6EMQMMtQE_ILpkZbB8StoVvTNxI6ilIhaNXW0l9F_omtn80lB9V8kf5haVUj3GU9rTOOO461k8Z6jUA== and event information is here: https://www.globenewswire.com/Tracker?data=ExGz5UObFBI-6FVyZpmdyFD5JCl5f8xr872plB5VAUsbsLD5xrJwpyteEGOTI2FjLF_nBKv-HrbuDqIZUsidYeQcnILAotZjRaTzOEPiCaz6Dcmko0AA07x0jx_TQxEfUYOgIXwvIiQKErupsibuEkgjeadQu0GFe8dIbfLdhzqo7U_8QJFsBvkpXxHHnagl .

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9658126-en) on February 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612267745"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612267745\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612267745?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612267745","market":"fut","top_or_hot":-1,"title":"Ernexa Therapeutics CEO Sanjeev Luther to Join Virtual Investor Closing Bell Series Webcast","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ernexa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> CEO Sanjeev Luther to Join Virtual Investor Closing Bell Series Webcast\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ernexa Therapeutics (Nasdaq: ERNA) said its President and CEO, Sanjeev Luther, will participate in the Virtual Investor Closing Bell Series on Wednesday, February 25, 2026 at 4:00 PM ET, providing a corporate overview and business outlook with a live Q&amp;A. Registration is available here: https://www.globenewswire.com/Tracker?data=RLDub8FFW7byVYLqZpCIzF9-aHU5aLAr8cfx7zgP335FFgqUD_hGfE9JePoYboIN-ts5V3N6EMQMMtQE_ILpkZbB8StoVvTNxI6ilIhaNXW0l9F_omtn80lB9V8kf5haVUj3GU9rTOOO461k8Z6jUA== and event information is here: https://www.globenewswire.com/Tracker?data=ExGz5UObFBI-6FVyZpmdyFD5JCl5f8xr872plB5VAUsbsLD5xrJwpyteEGOTI2FjLF_nBKv-HrbuDqIZUsidYeQcnILAotZjRaTzOEPiCaz6Dcmko0AA07x0jx_TQxEfUYOgIXwvIiQKErupsibuEkgjeadQu0GFe8dIbfLdhzqo7U_8QJFsBvkpXxHHnagl .\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9658126-en) on February 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ernexa Therapeutics CEO Sanjeev Luther to Join Virtual Investor Closing Bell Series Webcast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nErnexa Therapeutics CEO Sanjeev Luther to Join Virtual Investor Closing Bell Series Webcast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-20 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ernexa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> CEO Sanjeev Luther to Join Virtual Investor Closing Bell Series Webcast\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ernexa Therapeutics (Nasdaq: ERNA) said its President and CEO, Sanjeev Luther, will participate in the Virtual Investor Closing Bell Series on Wednesday, February 25, 2026 at 4:00 PM ET, providing a corporate overview and business outlook with a live Q&amp;A. Registration is available here: https://www.globenewswire.com/Tracker?data=RLDub8FFW7byVYLqZpCIzF9-aHU5aLAr8cfx7zgP335FFgqUD_hGfE9JePoYboIN-ts5V3N6EMQMMtQE_ILpkZbB8StoVvTNxI6ilIhaNXW0l9F_omtn80lB9V8kf5haVUj3GU9rTOOO461k8Z6jUA== and event information is here: https://www.globenewswire.com/Tracker?data=ExGz5UObFBI-6FVyZpmdyFD5JCl5f8xr872plB5VAUsbsLD5xrJwpyteEGOTI2FjLF_nBKv-HrbuDqIZUsidYeQcnILAotZjRaTzOEPiCaz6Dcmko0AA07x0jx_TQxEfUYOgIXwvIiQKErupsibuEkgjeadQu0GFe8dIbfLdhzqo7U_8QJFsBvkpXxHHnagl .\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9658126-en) on February 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL2nmjv9:1","article_id":"2612267745","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612267745","pubTimestamp":1771596311,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4588":"碎股","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","ERNA":"Eterna Therapeutics Inc.","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD"},"translate_title":"Ernexa Therapeutics首席执行官Sanjeev Luther将参加虚拟投资者收盘系列网络广播","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ERNA":0.9},"content_text":"Ernexa Therapeutics CEO Sanjeev Luther to Join Virtual Investor Closing Bell Series Webcast\n    \n\n        Ernexa Therapeutics (Nasdaq: ERNA) said its President and CEO, Sanjeev Luther, will participate in the Virtual Investor Closing Bell Series on Wednesday, February 25, 2026 at 4:00 PM ET, providing a corporate overview and business outlook with a live Q&A. Registration is available here: https://www.globenewswire.com/Tracker?data=RLDub8FFW7byVYLqZpCIzF9-aHU5aLAr8cfx7zgP335FFgqUD_hGfE9JePoYboIN-ts5V3N6EMQMMtQE_ILpkZbB8StoVvTNxI6ilIhaNXW0l9F_omtn80lB9V8kf5haVUj3GU9rTOOO461k8Z6jUA== and event information is here: https://www.globenewswire.com/Tracker?data=ExGz5UObFBI-6FVyZpmdyFD5JCl5f8xr872plB5VAUsbsLD5xrJwpyteEGOTI2FjLF_nBKv-HrbuDqIZUsidYeQcnILAotZjRaTzOEPiCaz6Dcmko0AA07x0jx_TQxEfUYOgIXwvIiQKErupsibuEkgjeadQu0GFe8dIbfLdhzqo7U_8QJFsBvkpXxHHnagl .\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9658126-en) on February 20, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}